Celcuity ( (CELC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celcuity’s stock surged after Wells Fargo initiated coverage with a Buy rating, highlighting the promising VIKTORIA-1 PI3KCA mutant readout and the market potential of gedatolisib in breast cancer treatment. Despite these opportunities, the current stock price does not fully capture this potential, even as the company reported a quarterly GAAP net loss of $43.8 million. However, increased insider selling activity may affect market perception negatively.
More about Celcuity
YTD Price Performance: 667.48%
Average Trading Volume: 1,115,337
Technical Sentiment Signal: Buy
Current Market Cap: $4.71B
For further insights into CELC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.